SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
|
|
- Ruby Austin
- 6 years ago
- Views:
Transcription
1 1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive to improve the outcomes and quality of life for children with cancer and blood disorders. The initiative has established a strong and formal partnership between SickKids, represented by key healthcare professionals, and six countries in the Caribbean: The Bahamas, Barbados, Jamaica, St. Lucia, St. Vincent and the Grenadines and Trinidad and Tobago. Inter-professional leaders from government, hospitals and academia are working collaboratively to implement a comprehensive strategy to build sustainable capacity in the identification and management of children with cancer and blood disorders in the Caribbean. This Guidance Document outlines the recommendations for the prevention and management of chemotherapy and /or radiation-induced nausea and vomiting in children diagnosed with cancer in the Caribbean. It was developed by adapting the guidelines listed in Section 5.0 to reflect the resources available in the partnering Caribbean countries. 1.1 Disclaimer This guidance document ( Guidance Document ) is intended solely for healthcare providers who are collaborators in the ( Collaborators ). The Guidance Document is a general guide to appropriate practice, to be followed only subject to the judgment of a patient's attending physician, taking into consideration all available information related to the condition of the patient and after review of the benefits and risks of the proposed course of action with the patient (if of an appropriate age) and/or the patient s parents or guardians. The Guidance Document has been specifically tailored for use at Collaborators institutions taking into consideration available health care resources and other relevant contextual factors in Collaborators countries. The Guidance Document is NOT intended for use by patients or their families and is not designed or intended to constitute medical advice or to be used for diagnosis. The Guidance Document is NOT a substitute for the personalized judgment and care provided by trained medical professionals. Every effort has been made to ensure that the information provided in the Guidance Document is accurate and in accordance with the standards accepted at the time it was created, however new research and experience may result in changes to these standards. In all cases, you, in your role as the patient s physician and the SCI lead physician for the relevant participating SCI country, are responsible for ensuring that the recommendations detailed below comply with all applicable local laws, statutes and regulations. By viewing and using any information derived from the Guidance Document, you, in your role as the patient s responsible physician, hereby waive any claims, causes of action and demands, whether in tort or contract, against any of the Collaborators (including their employees, physicians, directors and agents) in any way related to use of the Guidance Document or the information derived from it. Page 1 of 14
2 2.0 Definitions and Abbreviations CINV: chemotherapy induced nausea and vomiting IV: Intravenous PO: oral Chemotherapy block: series of consecutive days that chemotherapy is given within a treatment plan or protocol 3 phases of CINV: a. Acute - begins with the first dose of chemotherapy and continues for 24 hours following the last dose of chemotherapy of the chemotherapy block b. Delayed - begins at the end of the acute phase and may persist for up to 7 days c. Anticipatory - any nausea or vomiting which occurs within 24 hours prior to the first chemotherapy dose of a chemotherapy block. Breakthrough CINV: vomiting, retching or significant nausea during the acute or delayed phases that occurs despite appropriate antiemetic prophylaxis Failure: of acute CINV prophylaxis - patient experiences more than 2 vomits or retches within a 24 hour period or 3 or more hours of significant nausea despite appropriate antiemetic prophylaxis Classfication of emetogenic potential of antineoplastic or radiation therapy: a. ly emetogenic - vomiting occurs in more than 90% of patients who are not given antiemetic prophylaxis b. ly emetogenic - vomiting occurs in 30 to 90% of patients who are not given antiemetic prophylaxis c. emetogenicity - vomiting occurs in 10 to less than 30% of patients who are not given antiemetic prophylaxis d. ly emetogenic - vomiting occurs in less than 10% of patients who are not given antiemetic prophylaxis. 3.0 Recommendations 3.1 Assessment of the emetogenicity potential of single and multiple antineoplastic agents and based on site of radiotherapy Refer to Table 1 and Table 2 respectively. This assessment is most relevant in patients who are naïve to antineoplastic agents or radiotherapy. The emetogenicity of multiple day antineoplastic therapy is classified based on the most highly emetogenic agent (see Table 1) given on each day of therapy. Assessment of regimen emetogenicity in patients who have received antineoplastic agents or radiotherapy in the past should incorporate an evaluation of the patient s nausea and vomiting experience during prior chemotherapy blocks. Page 2 of 14
3 3.2 Selection of Antiemetic Interventions For a chemotherapy-naïve patient, the emetogenicity of therapy should be ranked based on Table 1 and or Table 2, then the initial antiemetic regimen selected as outlined in Figure 1. Ondansetron IV/PO and granisetron IV/PO are considered to be equivalent. Choice of agent and formulation should be based on relative acquisition cost and availability. The use of dexamethasone may be contraindicated or recommended to be avoided in certain patients. This may be re-evaluated based on patient response after discussion with the patient s primary physician. 3.3 Adjunctive non-pharmacological interventions Dietary interventions may be effective in helping to control CINV. Consider recommending the following: eat smaller, more frequent meals reduce food aromas and other stimuli with strong odours avoid foods that are spicy, fatty or highly salty take antiemetics prior to meals use measures and foods (e.g. comfort foods ) that helped to minimize nausea in the past If available, the following may be effective: acupuncture, acupressure (e.g. Seabands ), guided imagery, music therapy, progressive muscle relaxation and psycho-educational support and information and virtual reality. 3.4 Interventions to treat breakthrough acute CINV Children who experience breakthrough acute nausea and vomiting: exclude other possible causes of nausea and vomiting administer lorazepam to treat episodes of nausea and vomiting (see Table 2) ensure that the prescribed antiemetic agents are appropriate based on the emetogenicity ranking of the antineoplastic therapy being administered.if not, adjust antiemetic prophylaxis accordingly. select antiemetic prophylaxis based on the emetogenicity ranking PLUS one level. For example, give antiemetic prophylaxis recommended for children receiving highly emetogenic chemotherapy to a child receiving moderately emetogenic chemotherapy. 3.5 Interventions to treat children who have experienced failure of acute CINV prophylaxis in past chemotherapy blocks For patients who have experienced failure of antiemetic prophylaxis, consider the following interventions the next time chemotherapy or radiotherapy is administered: incorporate the interventions which were successful to treat breakthrough nausea/vomiting during the last treatment cycle in children who failed while receiving ondansetron, administer granisetron select antiemetic prophylaxis based on the emetogenicity ranking PLUS one level Page 3 of 14
4 3.6 CINV in the Delayed Phase Patients who are at higher risk of developing CINV in the delayed phase include those who: experience nausea or vomiting during the acute phase are known to have experienced nausea or vomiting during the delayed phase of past cycles and/or have received highly or moderately emetogenic therapy Ondansetron and granisetron are not effective in preventing or treating CINV in the delayed phase. Consider dexamethasone (See Table 2) in patients at risk of delayed phase CINV. Patients at risk of delayed CINV who cannot receive dexamethasone and who are older than 1 year should receive metoclopramide (see Table 2). If metoclopramide is given, consider giving diphenhydramine concurrently to prevent extrapyramidal reactions. Antiemetics should be given on a round-the-clock basis until the patient is symptom-free for at least 24 hours and should be reinstituted should symptoms reappear within the first 5 to 7 days following antineoplastic therapy. If nausea and vomiting increase in severity or persist beyond 5 to 7 days following antineoplastic administration, exclude other possible causes of nausea and vomiting. 3.7 Anticipatory CINV Complete control of acute and delayed CINV best minimizes the risk of developing anticipatory CINV. Psychological interventions such as hypnosis or systematic desensitization may be offered if available. Lorazepam (see Table 2) once at bedtime and once on the day prior to the administration of chemotherapy may also be used to prevent or treat anticipatory CINV. 3.8 Nausea and Vomiting due to Radiation Guidance regarding the selection of antiemetic prophylaxis for radiation-induced nausea and vomiting is presented in Table Radiation Somnolence Syndrome This is an early to delayed adverse effect of cranial radiation which presents as extreme lethargy and signs of increased intracranial pressure including nausea and vomiting. It may be difficult to distinguish radiation somnolence syndrome from acute and delayed phase CINV. Page 4 of 14
5 4.0 References 1. Antiemetic Selection for Children Receiving Antineoplatics and/or Radiotherapy. In Chen, J and Lau, E. (Eds.). (2015) The Hospital for Sick Children Drug Handbook and Formulary. Toronto, ON. Lexicomp. 2. Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients (Accessed July 14, 2015, at 3. Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients (Accessed July 14, 2015, at 4. Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting due to Chemotherapy in Pediatric Cancer Patients (Accessed July 14, 2015 at 5. Basch E, Prestrud A, Hesketh P, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology 2011; 29: Salvo N, Doble B, Khan L, et al. Prophylaxis of radiation-induced nausea and vomiting using 5- hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiation Oncology Biol Phys 2012: 82: Guidance Document Group This Guidance Document is adapted from the SickKids Clinical Practice Guideline Antiemetic Selection for Children Receiving Antineoplastics and/or Radiotherapy (2013) 1 ; the Pediatric Oncology Group of Ontario (POGO) Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients 2 ; POGO Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients 3 ; POGO Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting due to Chemotherapy in Pediatric Cancer Patients 4 and Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update 5. The individuals included below have participated in the development of this Guidance Document: L. Lee Dupuis, RPh, ACPR, FCSHP, PhD, Health Clinician Scientist, Research Institute, The Hospital for Sick Children, Toronto, Canada Alicia Koo, RPh, PharmD, ACPR, BScPhm, HonBSc, Clinical Pharmacy Manager, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada Page 5 of 14
6 6.0 Reviewers Strategic input to guide the development of this Guidance Document was solidified from and provided by the following Caribbean physicians. List of reviewers: Dr. Paula Michele Lashley, Queen Elizabeth Hospital, Barbados Dr. Corrine SinQuee-Brown, Paediatric Haematologist/Oncologist, Princess Margaret Hospital, The Bahamas Dr. Sharon McLean-Salmon, Bustamante Hospital for Children, Jamaica Dr. Michelle Reece-Mills, University Hospital of the West Indies, Jamaica Dr. Curt Bodkyn, Eric Williams Medical Sciences Complex, Trinidad and Tobago Dr. Sanjay Lalchandani, Eric Williams Medical Sciences Complex, Trinidad and Tobago Dr. Pauline Balkaransingh, Eric Williams Medical Sciences Complex, Trinidad and Tobago Page 6 of 14
7 Figure 1: Summary of the Recommendations Regarding Prevention of Acute AINV in Children Receiving Antineoplastic Medication Corticosteroids permitted ondansetron OR granisetron + dexamethasone emetogenic risk Corticosteroids contraindicated ondansetron OR granisetron + chlorpromazine OR nabilone Antineoplastic Agents with HIGH Emetic Risk Single agent antineoplastic therapy Altretamine Carboplatin Carmustine > 250 mg/m 2 Cisplatin Cyclophosphamide 1 g/m 2 Cytarabine 3 g/m 2 /dose Dacarbazine Dactinomycin Mechlorethamine Methotrexate 12 g/m 2 Procarbazine (oral) Streptozocin Thiotepa 300 mg/m 2 Multiple agent antineoplastic therapy With the exceptions listed below, emetogenicity is classified based on the most highly emetogenic agent. The following are also classified as high emetic risk: Cyclophosphamide + anthracycline Cyclophosphamide + doxorubicin Cyclophosphamide + epirubicin Cyclophosphamide + etoposide Cytarabine mg/m 2 + daunorubicin Cytarabine 300 mg/m 2 + etoposide Cytarabine 300 mg/m 2 + teniposide Doxorubicin + ifosfamide Doxorubicin + methotrexate 5 g/m 2 Etoposide + ifosfamide Multi-day antineoplastic therapy Emetogenicity is classified based on the most highly emetogenic agent on each day of therapy. Antiemetic Dosage Recommendations for Children receiving HIGHLY Emetogenic Antineoplastic Therapy Drug Dose Ondansetron Granisetron Dexamethasone Chlorpromazine Nabilone 5 mg/m 2 /dose (0.15 mg/kg/dose) IV/PO pre-therapy x 1 and then q8h 40mcg/kg/dose IV as a single daily dose OR 40mcg/kg/dose PO q12h < 12 yrs : 6 mg/m 2 /dose IV/PO pre-therapy x 1 and then q6h 12 yrs: 20 mg IV/PO pre-therapy and then q24h 0.5mg/kg/dose IV q6h < 18 kg: 0.5 mg/dose PO twice daily 18 to 30 kg: 1 mg/dose PO twice daily > 30 kg: 1 mg/dose PO three times daily Maximum: 0.06 mg/kg/day Page 7 of 14
8 emetogenic risk Corticosteroids permitted Corticosteroids contraindicated ondansetron OR granisetron + dexamethasone ondansetron + chlorpromazine OR metoclopramide OR nabilone Antineoplastic Agents with MODERATE Emetic Risk Single agent antineoplastic therapy Aldesleukin > 12 to 15 million units/m 2 Amifostine > 300 mg/m 2 Arsenic trioxide Azacitidine Bendamustine Busulfan Carmustine 250 mg/m 2 Clofarabine Cyclophosphamide < 1 g/m 2 Cyclophosphamide (oral) Cytarabine > 200 mg to < 3 g/m 2 Daunorubicin Doxorubicin Epirubicin Etoposide (oral) Idarubicin Ifosfamide Imatinib (oral) Intrathecal therapy (methotrexate, hydrocortisone & cytarabine) Irinotecan Lomustine Melphalan > 50 mg/m 2 Methotrexate 250 mg to < 12 g/m 2 Oxaliplatin > 75 mg/m 2 Temozolomide (oral) Vinorelbine (oral) Multiple agent antineoplastic therapy With the exceptions listed under high emetic risk, emetogenicity is classified based on the most highly emetogenic agent. Multi-day antineoplastic therapy Emetogenicity is classified based on the most highly emetogenic agent on each day of therapy. Antiemetic Dosage Recommendations for Children receiving MODERATELY Emetogenic Antineoplastic Therapy Drug Ondansetron Granisetron Dexamethasone Chlorpromazine Metoclopramide Nabilone Dose 5 mg/m 2 /dose (0.15 mg/kg/dose; maximum 8 mg/dose) IV/PO pretherapy x 1 and then q12h 40mcg/kg/dose IV as a single daily dose OR 40mcg/kg/dose PO q12h 0.6m 2 : 2mg/dose IV/PO q12h > 0.6m 2 : 4mg/dose IV/PO q12h 0.5mg/kg/dose IV q6h 1 mg/kg/dose IV pre-therapy x 1 then mg/kg/dose PO q6h Give diphenhydramine (1.25mg/kg/dose IV/PO up to q6h) or benztropine (children >3 years: mg/kg/dose IV 1-2 times/day ; max 2mg/dose) concurrently. < 18 kg: 0.5 mg/dose PO twice daily 18 to 30 kg: 1 mg/dose PO twice daily > 30 kg: 1 mg/dose PO three times daily Maximum: 0.06 mg/kg/day Page 8 of 14
9 emetogenic risk ondansetron OR granisetron Antineoplastic Agents with LOW Emetic Risk Single agent antineoplastic therapy Amifostine 300 mg/m 2 Amsacrine Bexarotene Busulfan (oral) Capecitabine Cytarabine 200 mg/m 2 Docetaxel Doxorubicin (liposomal) Etoposide Fludarabine (oral) 5-Fluorouracil Gemcitabine Ixabepilone Methotrexate >50 mg/m 2 to <250 mg/m 2 Mitomycin Mitoxantrone Nilotinib Paclitaxel Paclitaxel-albumin Pemetrexed Teniposide Thiotepa <300 mg/m 2 Topotecan Vorinostat Multiple agent antineoplastic therapy With the exceptions listed under high emetic risk, emetogenicity is classified based on the most highly emetogenic agent. Multi-day antineoplastic therapy Emetogenicity is classified based on the most highly emetogenic agent on each day of therapy. Antiemetic Dosage Recommendations for Children receiving LOW Emetic Risk Antineoplastic Therapy Drug Ondansetron Granisetron Dose 10 mg/m 2 /dose (0.3 mg/kg/dose; maximum 16 mg/dose) IV/PO pre-therapy x 1 40mcg/kg/dose IV/PO pre therapy x 1 Page 9 of 14
10 emetogenic risk no routine prophylaxis Alemtuzumab Alpha interferon Aspagarinase (IM or IV) Bevacizumab Bleomycin Bortezomib Cetuximab Chlorambucil (oral) Cladribine (2-chlorodeoxyadenosine) Dasatinib Decitabine Denileukin diftitox Dexrazoxane Antineoplastic Agents with MINIMAL Emetic Risk Single agent antineoplastic therapy Erlotinib Fludarabine Gefitinib Gemtuzumab ozogamicin Hydroxyurea (oral) Lapatinib Lenalidomide Melphalan (oral low-dose) Mercaptopurine (oral) Methotrexate 50 mg/m 2 Nelarabine Panitumumab Pentostatin Rituximab Sorafenib Sunitinib Temsirolimus Thalidomide Thioguanine (oral) Trastuzumab Valrubicin Vinblastine Vincristine Vindesine Vinorelbine For multiple agent and multi-day antineoplastic therapy Please refer to recommendations in emetic risk table. Page 10 of 14
11 Table 1: Emetogenicity Rankings of Antineoplastic Agents in Alphabetical Order Note: All agents are given intravenously (IV) unless otherwise stated. *Pediatric evidence available Antineoplastic Agent 5-Fluorouracil Aldesleukin > 12 to 15 million units/m 2 Alemtuzumab Alpha interferon Amifostine > 300 mg/m 2 Amifostine 300 mg/m 2 Amsacrine Anthracycline + cyclophosphamide *Cyclophosphamide + doxorubicin *Cyclophosphamide + epirubicin Arsenic trioxide Aspagarinase (IM or IV) Azacitidine Bleomycin Bortezomib Busulfan Busulfan (oral) Capecitabine Carboplatin* Carmustine > 250 mg/m 2 Carmustine 250 mg/m 2* Cetuximab Chlorambucil (oral) Cisplatin* Cladribine (2-chlorodeoxyadenosine) Clofarabine* Cyclophosphamide (oral) Cyclophosphamide < 1 g/m 2* Cyclophosphamide 1 g/m 2* Cyclophosphamide + anthracycline *Cyclophosphamide + doxorubicin *Cyclophosphamide + epirubicin Cyclophosphamide + etoposide Cytarabine > 200 mg to < 3 g/m 2 Cytarabine 200 mg/m 2 Level of Emetic Risk Page 11 of 14
12 Cytarabine 3 g/m 2 /dose* Cytarabine mg/m 2 + daunorubicin* Cytarabine 300 mg/m 2 + etoposide* Cytarabine 300 mg/m 2 + teniposide* Cytarabine, methotrexate + hydrocortisone: Intrathecal therapy* Dacarbazine Dactinomycin* Daunorubicin* Daunorubicin + cytarabine mg/m 2 * Dasatinib Decitabine Dexrazoxane Docetaxel Doxorubicin (liposomal) Doxorubicin* Doxorubicin + cyclophosphamide* Doxorubicin + ifosfamide* Doxorubicin + methotrexate 5 g/m 2 Epirubicin Epirubicin + cyclophosphamide* Etoposide Etoposide (oral) Etoposide + cyclophosphamide* Etoposide + cytarabine 300 mg/m 2 * Etoposide + ifosfamide* Fludarabine Fludarabine (oral) Gemcitabine Gemtuzumab ozogamicin Hydrocortisone, cytarabine + methotrexate: Intrathecal therapy* Hydroxyurea (oral) Idarubicin Ifosfamide Ifosfamide + doxorubicin* Ifosfamide + etoposide* Imatinib (oral) Intrathecal therapy (methotrexate, hydrocortisone & cytarabine)* Irinotecan Ixabepilone Lomustine Mechlorethamine Page 12 of 14
13 Melphalan (oral low-dose) Melphalan > 50 mg/m 2 Mercaptopurine (oral) Methotrexate > 50 mg/m 2 to < 250 mg/m 2 Methotrexate 50 mg/m 2 Methotrexate 12 g/m 2* Methotrexate 250 mg to < 12 g/m 2 Methotrexate 5 g/m 2 + Doxorubicin Methotrexate, hydrocortisone + cytarabine: Intrathecal therapy* Mitomycin Mitoxantrone Nelarabine Nilotinib Oxaliplatin > 75 mg/m 2 Paclitaxel Paclitaxel-albumin Procarbazine (oral) Rituximab Sorafenib Streptozocin Sunitinib Temozolomide (oral) Temsirolimus Teniposide Teniposide + cytarabine 300 mg/m 2 * Thalidomide Thioguanine (oral) Thiotepa < 300 mg/m 2 Thiotepa 300 mg/m 2* Topotecan Trastuzumab Vinblastine Vincristine Vindesine Vinorelbine Vinorelbine (oral) Vorinostat Page 13 of 14
14 Table 2: Recommended antiemetics and doses for anticipatory CINV, breakthrough CINV, failure of CINV prophylaxis and delayed phase CINV. See text for details regarding antiemetic choice. Antiemetic Agent Therapy Emetogenicity Dose Anticipatory CINV: Lorazepam All mg/kg/dose (maximum 2mg/dose) IV/PO/SL the night before and the morning of subsequent antineoplastic therapy Breakthrough CINV or Failure of Prophylaxis in the Acute Phase: Lorazepam All mg/kg/dose (max 2 mg/dose ) IV/PO/SL q6h PRN Delayed phase CINV: Dexamethasone All 4.5 mg/m 2 /dose (maximum 8 mg/dose) q12h PO Metoclopramide All 0.1 to 0.2mg/kg/dose PO/IV q6h Consider the concurrent use of diphenhydramine to prevent extrapyramidal effects. Table 3: Acute emetogenic potential of radiotherapy Site of Radiation Therapy Craniospinal Half-body Total body irradiation Total Nodal Irradiation Cranium Upper abdomen Upper body Head and neck er thorax region Pelvis Extremities Breast Level of Emetogenic Risk Page 14 of 14
Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationDescription The following are synthetic cannabinoids requiring prior authorization: dronabinol (Marinol, Syndros ), nabilone (Cesamet )
Clinical Policy: Nabilone (Cesamet), Dronabinol (Marinol, Syndros) Reference Number: CP.CPA.242 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.223 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zofran, Zuplenz) Reference Number: CP.CPA.173 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationREVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Pediatr Blood Cancer 2011;57:191 198 REVIEW Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients L. Lee Dupuis, MScPhm, ACPR, FCSHP,
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationThe AngCN Antiemetic Guidelines
The AngCN Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy AngCN Document Reference: AngCN-CCG-C31 CONTENTS 1.0 Introduction
More informationTrust Guideline for Prevention and Control of Chemotherapy and Radiotherapy Induced Nausea and Vomiting in Adults
A Clinical Guideline For Use in: Organisation-wide By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager:
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version Continue
Table of Contents Clinical in Oncology Version 2.2010 Continue www.nccn.org Version 2.2010, 04/07/2010 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationCOG Supportive Care Endorsed Guidelines Version date: December 11, 2017
COG Supportive Care Endorsed Guidelines The COG Supportive Care Endorsed Guidelines are comprised of -based guidelines which have been developed by other organizations endorsed by the Children s Oncology
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationANTIEMETICS UTILIZATION MANAGEMENT CRITERIA
ANTIEMETICS [Akynzeo, Anzemet, Cesamet, Emend, Sancuso, Varubi, Zuplenz ] DRUG CLASS: UTILIZATION MANAGEMENT CRITERIA 5-HT 3 Receptor Antagonists 5-HT 3 Receptor Antagonist and Substance P/Neurokinin (NK
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationAntiemetic Guidelines. Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy
Antiemetic Guidelines Guidelines for the Management of Nausea and Vomiting in Adult Patients Receiving Chemotherapy and/or Radiotherapy For approvals and version control see Document Management Record
More informationObjective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.
WARDS/DEPARTMENTS By: 0 01/09/019 1 of 3 Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites. Scope: All Black
More informationUse of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A
Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong
More informationECN Protocol Book. Antiemetic Guidelines for Adult Patients Receiving Chemotherapy and Radiotherapy
ECN Protocol Book Antiemetic Guidelines f Adult Patients Receiving Chemotherapy and Radiotherapy Name of person presenting document: Reason f document development: Names of development team: Specify groups
More informationAdverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and
35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting
More informationPrimary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site
Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kytril, Sancuso, Sustol) Reference Number: CP.PMN.74 Effective Date: 11.01.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Antiemesis. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2011 NCCN.org Continue Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationTo help doctors give their patients the best possible care, the American
Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific
More informationDRUG PROPERTIES YOU NEED TO KNOW
Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class
More informationAdult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference
CA2 Nationally standardised Dose banding for Adult Intravenous Anticancer Therapy (SACT) Scheme Name CA2: Nationally Standardised Dose Banding for Adult Intravenous Systemic Anticancer Therapy (SACT) Section
More informationRichard J. Gralla, MD Medical Director Quality of Life Research Associates New York, NY
Oncology Consultations Improving the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) A CE-Certified Activity Featuring Consultations With Supported by an educational grant from Eisai. Dannemiller
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationPatient-Centered Management of Chemotherapy-Induced Nausea and Vomiting
Clear and accurate communication between patients and health care teams is the key to successfully controlling chemotherapy-induced nausea and vomiting. Roseate Spoonbill_2005. Photograph courtesy of Henry
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationGUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.
Page 1 of 20 Guideline for the management of chemotherapy-induced nausea and vomiting, v2.1.1 GUIDELINE FOR THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING. Version: 2.1.0 Ratified by: Date
More informationCOST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!
UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationDOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days
Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationAntiemetics in chemotherapy
Antiemetics in chemotherapy Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Directorate & Speciality Date of submission Date
More informationChemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care
Chemotherapy-induced Nausea and Vomiting: The Pharmacist s Role in Integrating Clinical Guidelines into Patient Care Presented as a Live Webinar Wednesday, April 13, 2016 12:00 p.m. 1:00 p.m. ET Tuesday,
More informationICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced
ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationDisclosure. Objectives. Objectives. Oncologic Emergency. Classification of Emergencies 1 3/2/2015
Disclosure Oncologic Emergencies and Acute Supportive Care of the Critically Ill Oncology Patient By: Kimberly Regis, Pharm.D. Broward Health Medical Center Pharmacy Resident 2014-2015 I do not have a
More informationUpdate on antiemetics, what is new and future directions. Karin Jordan University of Halle
Update on antiemetics, what is new and future directions Karin Jordan University of Halle History of Antiemetics Controlling Chemotherapy-Induced EMESIS: Progress Over The Past 30 Years: Efficacy 5-Day
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Characterization of the generated hipsc lines a) Western blot analysis indicating the efficient downregulation of p53 upon knockdown in three hipsc lines (
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationChemotherapy-Induced Nausea and Vomiting: Strategies for Achieving Optimal Control
Chemotherapy-Induced Nausea and Vomiting Strategies for Achieving Learning Objectives Describe the challenges of assessing nausea in patients undergoing chemotherapy and the impact of nausea and also vomiting
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationCLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS
CLINICAL GUIDANCE FOR THE PREVENTION AND MANAGEMENT OF CHEMOTHERAPY AND RADIOTHERAPY INDUCED NAUSEA AND VOMITING IN ADULTS Procedure reference: Document owner: 2196 Version: V2.1 Robert Duncombe, The Director
More informationAD regimen, 576 adrenal steroid inhibitor. aminoglutethimide, 23 25
A 640 Index Index abiraterone acetate, 5 7 Abraxane. See albuminbound paclitaxel ABVD regimen, 57, 540 ABV regimen, 519 520 AC docetaxel regimen, 476, 478 acetaminophen busulfan and, 71 AC regimen, 475,
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More information1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.
Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant
More informationPart B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care
Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot
More informationAcute Lymphocytic Leukemia
Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin
More informationGastrointestinal Alterations
Gastrointestinal Alterations Nancy Thompson, RN, MS, AOCNS Swedish Cancer Institute Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia GI Alterations The Chinese do not draw any distinction
More informationGuidelines for Assessment and Management of Nausea and Vomiting
Guidelines for Assessment and Management of Nausea and Vomiting To Prevent and Manage Nausea and Vomiting Induced by Chemotherapy Or Related to Other Oncologic Etiologies Dana Farber Cancer Institute Brigham
More informationCLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical and nursing staff working with paediatric oncology patients. 2. The
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More informationAntiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org Continue Version 1.2015, 04/01/15 National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationPart B payment for drugs in Medicare 0
Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More information